key: cord-0049984-qtk86k0o
authors: Burra, Patrizia; Tacke, Frank; Ratziu, Vlad; Zeuzem, Stefan; Sangro, Bruno; Angeli, Paolo
title: From the Editor's Desk...
date: 2020-09-15
journal: J Hepatol
DOI: 10.1016/j.jhep.2020.07.011
sha: bd88ce34b20cbf0d21f8a6f3094bcf85fc3b9fdd
doc_id: 49984
cord_uid: qtk86k0o

nan

From the Editor's Desk... Patrizia Burra*, Frank Tacke, Vlad Ratziu, Stefan Zeuzem, Bruno Sangro, Paolo Angeli

The PREDICT study uncovers 3 clinical courses of acutely decompensated cirrhosis with distinct pathophysiology

In the PREDICT study, a European, prospective, observational study, Trebicka et al. aim to characterize the clinical course of acute decompensation (AD) of cirrhosis in 1,071 patients. Three groups of patients were identified: patients with pre-acute-on-chronic liver failure (ACLF), who developed ACLF and had 3-month and 1-year mortality rates of 53.7% and 67.4%, respectively; patients with unstable decompensated cirrhosis who did not develop ACLF but required > − 1 hospital readmission, and had mortality rates of 21.0% and 35.6%, respectively; patients with stable decompensated cirrhosis who neither developed ACLF nor were readmitted, and had a 1-year mortality rate of only 9.5%. The grade of systemic inflammation and the prevalence of surrogates of severe portal hypertension were significantly different between the 3 groups. Thus, the authors concluded that AD without ACLF is a heterogeneous condition with 3 different clinical courses and 2 major pathophysiological mechanisms: systemic inflammation and portal hypertension. 

SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with Liver enzyme abnormalities are common in patients with coronavirus disease 2019 . Wang et al. investigated 156 patients diagnosed with COVID-19 from 2 centers in China, and compared clinical features between patients with and without elevated aminotransferases. The liver enzyme abnormalities were associated with disease severity. Postmortem liver biopsies were obtained from 2 cases who had elevated aminotransferases. Ultrastructural examination identified typical coronavirus particles characterized by spike structures in the cytoplasm of hepatocytes. SARS-CoV-2-infected hepatocytes displayed conspicuous mitochondrial swelling, endoplasmic reticulum dilatation, and glycogen granule decrease. Histologically, massive hepatic apoptosis and certain binuclear hepatocytes were observed. The findings are already being critically discussed and challenged within the scientific community (see Letters to Editor).

Liver transplantation during a pandemic: A case for quadripartite equipoise

The outbreak of COVID-19 has vastly increased the operational burden on health care systems worldwide. For patients with end-stage liver failure, liver transplantation is the only option. Chew and coworkers propose a novel ethical framework, the quadripartite equipoise (QE) score, based on 4 factors: recipient outcome, donor/graft safety, waiting list mortality and health care resources. Seventeen liver transplant centers from 12 countries across 4 continents were involved in the study and 10/17 centers opted to limit transplant activity in response to the pandemic, favoring a "sickest-first" approach. Conversely, some larger centers opted to continue routine transplant activity in order to balance waiting list mortality. The fluctuation of the QE score over time accurately reflects the dynamic changes in the ethical tensions surrounding transplant activity in a pandemic and serves as an applicable framework to guide regulation of transplant activity in response to the increasing burden on healthcare systems.

Unexpected direct antifibrotic effects of ACC inhibition on stellate cells Acetyl-CoA carboxylase (ACC) promotes de novo lipogenesis and inhibits fatty acid oxidation in hepatocytes. Thus, ACC inhibitors (e.g. firsocostat) are currently being tested in clinical trials for nonalcoholic steatohepatitis (NASH). Bates and coworkers now provide compelling data that ACC inhibition has additional direct antifibrotic effects in hepatic stellate cells (HSCs). Using mechanistic studies with primary HSCs and fibrotic mouse models, ACC inhibition prevented fibrogenic HSC activation. Mechanistically, HSCs apparently require ACC and de novo lipogenesis for their activation towards collagen-producing myofibroblasts. These data suggest an unexpected additional antifibrotic activity of ACC inhibition beyond their anti-steatotic effects on hepatocytes, which will inform the further development of this drug class for patients with NASH. Molecular mechanism underlying de novo lipogenesis and fatty liver disease in response to chronic alcohol exposure Chronic alcohol consumption leads to fatty liver and many features similar to nonalcoholic fatty liver disease (NAFLD), but the underlying molecular mechanisms are, surprisingly, rather poorly understood. Song and coworkers now demonstrate that the endoplasmic reticulum stressinduced upregulation of liver nicotinamide methyltransferase (NNMT), the enzyme catalyzing nicotinamide degradation using s-adenosylmethionine as a methyl donor, is a pathological driver of hepatic de novo lipogenesis and fatty acid accumulation in mouse models. Intriguingly, therapeutic NNMT inhibition protected against fatty liver development following chronic alcohol consumption, which was associated with suppressed de novo lipogenic activity and enhanced AMPK activation. These data might provide a basis to develop novel treatment approaches for alcoholrelated fatty liver disease. From discovery of a new genetic factor to its pathogenic involvement in NAFLD: the GTPase IFGGA2 prevents hepatic lipid accumulation Genetic factors are relevant to the pathogenesis of NAFLD, but their mechanistic contribution to a complex disease such as NASH is often blurry. Schwerbel and coworkers discovered 2 immunityrelated GTPases (Ifgga2, Ifgga4) in mouse models and human samples that prevent hepatic lipid storage. On a mechanistic level, IFGGA2 interacts with ATGL, which binds the autophagy protein LC3B. IFGGA2, ATGL and LC3B co-localize at lipid droplets, and overexpression of IFGGA2 reduces hepatic lipid storage. This study is an impressive example of how to identify new genetic factors as well as their mechanistic contribution. It will now be important to translate this discovery into improved diagnostics or therapeutics for patients.

HSCs are the key collagen-producing cells in liver fibrosis. HSCs characteristically express cytoglobin (CYGB), a reactive oxygen species scavenger. Okina and coworkers explored the role of CYGB in HSC activation and NASH. In human livers and in vitro HSCs, TGF-b1 suppressed CYGB expression through phosphorylated SMAD2 and the M1 repressor isoform of SP3. With TGF-b1-induced CYGB suppression, human HSCs are more susceptible to oxidative stress and oxidative DNA damage. This mechanism appears to contribute to human NASH fibrosis and might be an interesting interventional antifibrotic target. pioglitazone (a c agonist) and GW501516 (a d agonist) in mouse models. Lanifibranor improved steatohepatitis (and each one of its components) as well as fibrosis to a greater degree than any of the single isoform PPAR agonists. The antifibrotic effect was confirmed by reduction of markers of activation in human stellate cells. Importantly, lanifibranor reduced infiltrating monocytes and macrophages in the liver. Collectively, these data show that lanifibranor synergistically combines differential effects of single PPAR agonists in experimental steatohepatitis: amelioration of liver steatosis was mostly achieved via PPARa activation, whereas PPARd controlled hepatic inflammation and macrophage activation and PPARc induced a direct deactivation of stellate cells. The positive histological results from a phase II study recently reported suggest the translational value of these results.

Efficacy of NS5A inhibitors against "unusual" and potentially difficult-totreat HCV subtypes HCV is highly diverse with more than 100 subtypes grouped into 8 genotypes. Genotypes 1 and 3 are the most prevalent genotypes worldwide. Genotype 4 is most commonly detected in the Middle East and sub-Saharan Africa while genotype 6 is mainly found in Southeast Asia. The prevalence of genotypes 4 and 6 is increasing in North America and Europe due to migration. The efficacy of NS5A inhibitors against several less common subtypes of HCV is poorly characterized. Some subtypes commonly harbor amino acid residues as wild-type in NS5A that may confer resistance to direct-acting antivirals in other common subtypes. Nguyen et al. tested the efficacy of daclatasvir, elbasvir, ledipasvir, pibrentasvir and velpatasvir against these subtypes using the SGR-JFH1 replicon backbone. NS5A inhibitors showed different levels of efficacy with only pibrentasvir effective against all tested subtypes. The high ledipasvir EC 50 values with the Q30R substitution, 4r L31M and 4r Y93H may explain the treatment failure in patients who were infected with these viruses and treated with ledipasvir + sofosbuvir. The study also shows the ineffectiveness of the first generation NS5A inhibitors against 6u and 6v, and Cloned NS5A sequences from "unusual" subtypes 1l, 3b, 3g, 4r, 6u and 6v 

Nguyen et al., 2020. Efficacy of NS5A inhibitors against "unusual" and potentially difficult-to-treat HCV subtypes confirms the inherent resistance of 3b and 3g to most NS5A inhibitors.

Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B Concomitant NAFLD is common in patients with chronic hepatitis B (CHB) infection, although its impact on liverrelated outcomes remains controversial. Lung-Yi Mak et al. studied the effect of hepatic steatosis on the risk of fibrosis progression and HBsAg seroclearance. The authors found that the presence of hepatic steatosis was associated with a significantly higher chance of HBsAg seroclearance. However, the rate of liver fibrosis progression in patients with persistent severe steatosis was higher than in those without steatosis (41.3% vs. 23%). Persistent severe hepatic steatosis was independently associated with fibrosis progression. Taken together, co-existing fatty liver disease in patients with chronic viral hepatitis B infection leads to worsening of liver fibrosis, but also increases the chance of cure from HBV.

The efficacy and safety of b-blockers in advanced cirrhosis is still controversial. Alvarado-Tapias et al. aimed to evaluate the systemic and splanchnic hemodynamic effects of b-blockers in decompensated vs. compensated cirrhosis and investigate the influence of systemic hemodynamic changes on survival in decompensated cirrhosis. Under b-blockers, decompensated patients had a lower portal-pressure decrease and greater reductions in heart-rate and cardiac output (CO). Among patients with decompensated cirrhosis, those who died had a greater decrease in CO with b-blockers than those who survived. CO under b-blockers independently predicted death by competing-risk regression analysis, with good diagnostic accuracy. Thus, the authors concluded that the shortterm effect of b-blockers on CO might adversely influence survival in decompensated cirrhosis, which suggests that careful dose titration with non-invasive CO monitoring might be helpful in these patients.

Targeted lipidomics reveals extensive changes in the blood lipid mediator profile in acutely decompensated cirrhosis ACLF, a syndrome that develops in patients with acutely decompensated cirrhosis, is characterized by intense systemic inflammation, multiorgan failure and high short-term mortality. In this study, López-Vicario et al. assessed the profile of lipid mediators in plasma from patients with AD of cirrhosis, with and without ACLF, and healthy individuals. Fifty-nine out of 100 lipid mediators were detected in plasma from cirrhotic patients, of which 16 were significantly associated with the disease status. Among these, 11 lipid mediators distinguished patients at any stage from healthy individuals, whereas 2 lipid mediators, leukotriene E4 (LTE4) and 12-hydroxyheptadecatrienoic acid, both derived from arachidonic acid, shaped a minimal plasma fingerprint that discriminated patients with ACLF from those without ACLF. Levels of LTE4 distinguished ACLF grade 3 from ACLF grades 1 and 2, as well as correlating with the clinical course of the disease, and markers of inflammation and non-apoptotic cell death. Moreover, LTE4 together with LXA5 (derived from eicosapentaenoic acid) and EKODE (derived from linoleic acid) were associated with short-term mortality. Taken together, these findings led the authors to state that specific lipid mediator profiles are associated with severity and prognosis of patients with AD of cirrhosis.

Innate immunity in the liver cancer environment: Monocyte-neutrophil interactions control HCC progression Neutrophils are frequently found in the tumor environment of patients with hepatocellular carcinoma (HCC), but their function is incompletely understood. Peng and coworkers characterized and isolated different innate immune and stromal cells from patients with HCC to unravel interactions between the tumor and its immune environment. Tumorinfiltrating monocytes undergo a metabolic (glycolytic) switch and secrete neutrophil-attracting chemokines. These chemokines, together with monocytic cytokines and tumor-derived factors, recruit neutrophils to the tumor, where they receive pro-survival signals that differentiate them towards a tumor-and metastasis-promoting phenotype. Deciphering these interactions provides the foundation for modulating innate immune mechanisms in HCC in order to improve local and systemic therapies.

Contrary to other malignancies of the biliary tract, gallbladder cancer (GBC) is more frequent among women in most but not all geographical areas. Sex hormones may logically be involved in this imbalance. To better understand the role that reproductive factors may play in the etiology of biliary tract cancers (BTC), Jackson et al. have analyzedin the pooled data from 19 studies covering more than 1.5 million womenthe associations of parity, age at menarche, reproductive years, and age at menopause with BTC. The risk of GBC was associated with an increasing number of live births, and was highest for women with 5 or more live births compared to nulliparous women. GBC was also associated with an older age at menopause, with a HR of 1.26 for women with menopause at 50 to 54 years compared to those at 45 to 49 years. For age at menarche and reproductive years, the result differed according to ancestry. For Asian women, the risk of GBC increased with increasing age at menarche (HR of 1.15 per year) while for non-Asian women the risk increased with duration of reproductive years (HR of 1.13 per 5 years). Altogether, these results suggest that sex hormones may have distinct effects on cancers across the biliary tract and vary by geography.

A nomogram to predict postoperative complications in patients with HCC

The identification of patients who develop complications after liver resection is of the utmost importance, because of their impact on cost, morbidity and mortality. In addition to other variables, liver stiffness measured by transient elastography may predict liver failure in patients who undergo liver resection for HCC. However, liver failure is not the only complication that could be related to the degree of liver fibrosis. Serenari et al. retrospectively studied a series of 471 patients who had a liver resection performed for HCC between 2006 and 2016 at 2 large referral centers. Postoperative complications were scored using the comprehensive compli-cation index (CCI) that ranges from 0 (uneventful course) to 100 (death). Patients were classified as having severe complications when the CCI was > − 26.2, and 50 out of the 471 patients (10.6%) had such severe complications. A novel nomo-gram, combining age, MELD score, serum albumin and liver stiffness provided an excellent preoperative prediction of high CCI in patients with HCC. This predictive tool could be used as a reference for clinicians and surgeons.

Vlad Ratziu at Insitute for Cardiometabolism and Nutrition, Sorbonne Université and Hospital Pitié Salpêtrière